Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19

NCT04310865 is registered in ClinicalTrials.gov with Zhong Wang as lead sponsor.

NCT NCT04310865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04310865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Lead sponsor
Zhong Wang
Phase
Phase 2/3
Overall status
Suspended
Start date
November 30, 2021
Completion date
April 30, 2023
Enrollment
116 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chinese medicine, covid-19, severe pneumonia